Mild cognitive impairment in Parkinson's disease

Minerva Medica

Volumn 102, Issue 6, 2011, Pages 441-459

  Goldman, J G ^a   Litvan, I ^b  

^a RUSH UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer disease; Dementia; Parkinson disease; Psychomotor disorders

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ATOMOXETINE; BIOLOGICAL MARKER; CATECHOL METHYLTRANSFERASE; LEVODOPA; MEMANTINE; RASAGILINE; TAU PROTEIN;

AMNESIA; ATTENTION; CEREBROSPINAL FLUID; CLINICAL FEATURE; DEMENTIA; DEPTH PERCEPTION; EXECUTIVE FUNCTION; GASTROINTESTINAL SYMPTOM; GENETIC ANALYSIS; HIGH RISK PATIENT; HUMAN; HYPOMANIA; MILD COGNITIVE IMPAIRMENT; MOTOR DYSFUNCTION; NEUROIMAGING; PARKINSON DISEASE; PATHOGENESIS; REVIEW; SIDE EFFECT; SLEEP;

BIOLOGICAL MARKERS; HUMANS; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; PARKINSON DISEASE;

EID: 84857564714     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384-6. (Pubitemid 46184217)
2. Hughes TA, Ross HF, Mindham RH, Spokes EG. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand 2004;110:118-23. (Pubitemid 39044049)
3. Levy G, Tang MX, Louis ED, Cote LJ, Alfaro B, Mejia H et al. The association of incident dementia with mortality in PD. Neurology 2002;59:1708-13. (Pubitemid 35424451)
4. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837-44.
5. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000;48:938-42. (Pubitemid 30637303)
6. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005;20:1255-63. (Pubitemid 41645899)
7. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003,60:387-92. (Pubitemid 36314364)
8. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003;2:229-37. (Pubitemid 37443310)
9. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-707; quiz 837.
10. Janvin C, Aarsland D, Larsen JP, Hugdahl K. Neuropsychological profile of patients with Parkinson's disease without dementia. Dement Geriatr Cogn Disord 2003;15:126-31. (Pubitemid 36206641)
11. Pillon B BF, Levy R, Dubois B. Cognitive deficits and dementia in Parkinson's disease. In: Boller F, Cappa SF, editors. Handbook of neuropsychology. Amsterdam: Elsevier; 2001.
12. Pagonabarraga J, Kulisevsky J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B, Gironeil A. Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease. Mov Disord 2008;23:998-1005.
13. Association AP. Diagnostic and Statistical manual of mental disorders, text revision. 4th ed ed. Washington, DC: American Psychiatric Association; 2000.
14. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006;21:1343-9. (Pubitemid 44613283)
15. Aarsland D, Bronnick K, Ehrt U, De Deyn PP, Tekin S, Emre M et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007;78:36-42. (Pubitemid 46048261)
16. Williams-Gray CH, Goris A, Saiki M, Foltynie T, Compston DA, Sawcer SJ et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J Neurol 2009;256:493-8.
17. Seto-Salvia N, Clarimon J, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Combarros O et al. Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch Neurol 2011;68:359-64.
18. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-18. (Pubitemid 39603164)
19. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-8. (Pubitemid 29120227)
20. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007;130(Pt 7):1787-98. (Pubitemid 47343805)
21. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ et al. Mild cognitive impairment: ten years later. Arch Neurol 2009;66:1447-55.
22. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240-6. (Pubitemid 39222993)
23. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-9.
24. Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol 2003;60:1385-9. (Pubitemid 37248799)
25. Busse A, Hensel A, Guhne U, Angermeyer MC, Riedel-Heller SG. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology 2006;67:2176-85. (Pubitemid 46035473)
26. Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008;30:58-69. (Pubitemid 351311727)
27. Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C. Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Arch Neurol 2009,66:1151-7.
28. Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004;127(Pt 3):550-60. (Pubitemid 38295472)
29. Aarsland D, Brennick K, Larsen JP, Tysnes OB, Alves G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian Park West Study. Neurology 2009;72:1121-6.
30. Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007;22:1272-7. (Pubitemid 47325034)
31. Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B et al. MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD-MCI. Mov Disord 2011 [Epub ahead of print].
32. Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010;75:1062-9.
33. Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005;65:1239-45. (Pubitemid 41508217)
34. Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 1991;114(Pt 5):2095-122.
35. Owen AM, James M, Leigh PN, Summers BA, Marsden CD, Quinn NP et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 1992;115(Pt 6):1727-51. (Pubitemid 23054862)
36. Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, Middelkoop HA et al. Cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:1182-7. (Pubitemid 350057278)
37. Riedel O, Klotsche J, Spottke A, Deuschl G, Forstl H, Henn F et al. Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol 2008;255:255-64.
38. Sollinger AB, Goldstein FC, Lah JJ, Levey AI, Factor SA. Mild cognitive impairment in Parkinson's disease: subtypes and motor characteristics. Parkinsonism Relat Disord 2010;16:177-80.
39. Dalrymple-Alford JC, Livingston L, MacAskill MR, Graham C, Melzer TR, Porter RJ et al. Characterizing mild cognitive impairment in Parkinson's disease. Mov Disord 2011;26:629-36.
40. Mamikonyan E, Moberg PJ, Siderowf A, Duda JE, Have TT, Hurtig HI et al. Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. Parkinsonism Relat Disord 2009;15:226-31.
41. Lezak M. Executive functions. 3rd ed. New York, NY: Oxford University Press; 1995.
42. Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J Neurol 1997;244:2-8. (Pubitemid 26413891)
43. Alevriadou A, Katsarou Z, Bostantjopoulou S, Kiosseoglou G, Mentenopoulos G. Wisconsin Card Sorting Test variables in relation to motor symptoms in Parkinson's disease. Percept Mot Skills 1999,89:824-30.
44. Shipley BA, Deary IJ, Tan J, Christie G, Starr JM. Efficiency of temporal order discrimination as an indicator of bradyphrenia in Parkinson's disease: the inspection time loop task. Neuropsychologia 2002;40:1488-93. (Pubitemid 34249859)
45. Azuma T, Cruz RF, Bayles KA, Tomoeda CK, Montgomery EB Jr. A longitudinal study of neuropsychological change in individuals with Parkinson's disease. Int J Geriatr Psychiatry 2003;18:1115-20. (Pubitemid 38049245)
46. Cronin-Golomb A, Braun AE. Visuospatial dysfunction and problem solving in Parkinson's disease. Neuropsychology 1997;11:44-52. (Pubitemid 27086859)
47. Cummings JL, Darkins A, Mendez M, Hill MA, Benson DF. Alzheimer's disease and Parkinson's disease: comparison of speech and language alterations. Neurology 1988;38:680-4.
48. Grossman M, Carvell S, Gollomp S, Stern MB, Vernon G, Hurtig HI. Sentence comprehension and praxis deficits in Parkinson's disease. Neurology 1991;41:1620-6.
49. Henry JD, Crawford JR. Verbal fluency deficits in Parkinson's disease: a meta-analysis. J Int Neuropsychol Soc 2004;10:608-22. (Pubitemid 39077201)
50. Stern Y, Richards M, Sano M, Mayeux R. Comparison of cognitive changes in patients with Alzheimer's and Parkinson's disease. Arch Neurol 1993;50:1040-5. (Pubitemid 23301248)
51. Stebbins GT, Gabrieli JD, Masciari F, Monti L, Goetz CG. Delayed recognition memory in Parkinson's disease: a role for working memory? Neuropsychologia 1999;37:503-10. (Pubitemid 29138933)
52. Filoteo JV, Rilling LM, Cole B, Williams BJ, Davis JD, Roberts JW. Variable memory profiles in Parkinson's disease. J Clin Exp Neuropsychol 1997;19:878-88. (Pubitemid 28153416)
53. Weintraub D, Moberg PJ, Culbertson WC, Duda JE, Stern MB. Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. Cogn Behav Neurol 2004;17:195-200. (Pubitemid 40066236)
54. Naismith SL, Pereira M, Shine JM, Lewis SJ. How well do caregivers detect mild cognitive change in Parkinson's disease? Mov Disord 2011;26:161-4.
55. Dujardin K, Duhamel A, Delliaux M, Thomas-Anterion C, Destee A, Defebvre L. Cognitive complaints in Parkinson's disease: its relationship with objective cognitive decline. J Neurol 2010;257:79-84.
56. Rosenthal E, Brennan L, Xie S, Hurtig H, Milber J, Weintraub D et al. Association between cognition and function in patients with Parkinson disease with and without dementia. Mov Disord 2010;25:1170-6.
57. Dalrymple-Alford JC, Livingston L, Macaskill MR, Graham C, Melzer TR, Porter RJ et al. Characterizing mild cognitive impairment in Parkinson's disease. Mov Disord 2011 [In press].
58. Fournet N, Moreaud O, Roulin JL, Naegele B, Pellat J. Working memory functioning in medicated Parkinson's disease patients and the effect of withdrawal of dopaminergic medication. Neuropsychology 2000;14:247-53.
59. Pascual-Sedano B, Kulisevsky J, Barbanoj M, Garcia-Sanchez C, Campolongo A, Gironell A et al. Levodopa and executive performance in Parkinson's disease: a randomized study. J Int Neuropsychol Soc 2008;14:832-41.
60. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007;22:2314-24. (Pubitemid 351155975)
61. Troster AI. A Precis of Recent Advances in the Neuropsychology of Mild Cognitive Impairment(s) in Parkinson's Disease and a Proposal of Preliminary Research Criteria. J Int Neuropsychol Soc 2011:1-14.
62. Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D et al. A recommended scale for cognitive screening in clinical trials of Parkinson's disease. Mov Disord 2010;25:2501-7.
63. Kulisevsky J, Pagonabarraga J. Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment. Mov Disord 2009;24:1103-10.
64. Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 2009;73:1738-45.
65. Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010;75:1717-25.
66. Kalbe E, Calabrese P, Kohn N, Hilker R, Riedel O, Wittchen HU et al. Screening for cognitive deficits in Parkinson's disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument. Parkinsonism Relat Disord 2008;14:93-101. (Pubitemid 351726305)
67. Llebaria G, Pagonabarraga J, Kulisevsky J, Garcia-Sanchez C, Pascual-Sedano B, Gironeil A et al. Cutoff score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease. Mov Disord 2008;23:1546-50.
68. Villeneuve S, Rodrigues-Brazete J, Joncas S, Postuma RB, Latreille V, Gagnon JF. Validity of the Mattis Dementia Rating Scale to detect mild cognitive impairment in Parkinson's disease and REM sleep behavior disorder. Dement Geriatr Cogn Disord 2011;31:210-7.
69. Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM. L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berl) 1992;107:394-404.
70. Lewis SJ, Slabosz A, Robbins TW, Barker RA, Owen AM. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease. Neuropsychologia 2005;43:823-32. (Pubitemid 40248892)
71. Stern Y, Tetrud JW, Martin WR, Kutner SJ, Langston JW. Cognitive change following MPTP exposure. Neurology 1990;40:261-4. (Pubitemid 20099435)
72. Cools R, Barker RA, Sahakian BJ, Robbins TW. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 2001;11:1136-43. (Pubitemid 33108240)
73. Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Dubois B. Motivation, reward, and Parkinson's disease: influence of dopatherapy. Neuropsychologia 2002;40:2257-67. (Pubitemid 35303365)
74. Cools R, Lewis SJ, Clark L, Barker RA, Robbins TW. L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology 2007;32:180-9. (Pubitemid 44967796)
75. Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985;48:413-21. (Pubitemid 15064881)
76. Mattila PM, Roytta M, Lonnberg P, Marjamaki P, Helenius H, Rinne JO. Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathol 2001;102:160-6. (Pubitemid 32771664)
77. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318:121-34. (Pubitemid 39362633)
78. Tiraboschi P, Hansen LA, Alford M, Sabbagh MN, Schoos B, Masliah E et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000;54:407-11. (Pubitemid 30078073)
79. Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005;64:1404-10. (Pubitemid 40570509)
80. Adler CH, Caviness JN, Sabbagh MN, Shill HA, Connor DJ, Sue L et al. Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol 2010;120:827-8.
81. Mollenhauer B, Trenkwalder C, von Ahsen N, Bibl M, Steinacker P, Brechlin P et al. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord 2006;22:200-8. (Pubitemid 44310515)
82. Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 2008;64:850-5.
83. Compta Y, Marti MJ, Ibarretxe-Bilbao N, Junque C, Valldeoriola F, Munoz E et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord 2009;24:2203-10.
84. Alves G, Bronnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian Park West study. J Neurol Neurosurg Psychiatry 2010;81:1080-6.
85. Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010;75:1055-61.
86. Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C et al. CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010;25:2682-5.
87. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009;132:2958-69.
88. Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry 2007;78:254-9. (Pubitemid 46579662)
89. Apostolova LG, Beyer M, Green AE, Hwang KS, Morra JH, Chou YY et al. Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia. Mov Disord 2010;25:687-8.
90. Lee JE, Park HJ, Song SK, Sohn YH, Lee JD, Lee PH. Neuroanatomic basis of amnestic MCI differs in patients with and without Parkinson disease. Neurology 2010;75:2009-16.
91. Dalaker TO, Zivadinov R, Larsen JP, Beyer MK, Cox JL, Alves G et al. Gray matter correlations of cognition in incident Parkinson's disease. Mov Disord 2010;25:629-33.
92. Dalaker TO, Zivadinov R, Ramasamy DP, Beyer MK, Alves G, Bronnick KS et al. Ventricular enlargement and mild cognitive impairment in early Parkinson's disease. Mov Disord 2011;26:297-301.
93. Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008;70(16 Pt 2):1470-7. (Pubitemid 351521942)
94. Nobili F, Abbruzzese G, Morbelli S, Marchese R, Girtler N, Dessi B et al. Amnestic mild cognitive impairment in Parkinson's disease: a brain perfusion SPECT study. Mov Disord 2009;24:414-21.
95. Hosokai Y, Nishio Y, Hirayama K, Takeda A, Ishioka T, Sawada Y et al. Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment. Mov Disord 2009;24.854-62.
96. Hanagasi HA, Gurvit H, Unsalan P, Horozoglu H, Tuncer N, Feyzioglu A et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study. Mov Disord 2011 [Epub ahead of print].
97. Marsh L, Biglan K, Gerstenhaber M, Williams JR. Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord 2009;24:277-82.
98. Weintraub D, Mavandadi S, Mamikonyan E, Siderowf AD, Duda JE, Hurtig HI et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 2010;75:448-55.
99. Sinforiani E, Banchieri L, Zucchella C, Pacchetti C, Sandrini G. Cognitive rehabilitation in Parkinson's disease. Arch Gerontol Geriatr Suppl 2004,9:387-91. (Pubitemid 38822889)
100. Paris AP, Saleta HG, de la Cruz Crespo Maraver M, Silvestre E, Freixa MG, Torrellas CP et al. Blind randomized controlled study of the efficacy of cognitive training in Parkinson's disease. Mov Disord 2011;26:1251-8.